The legal action centers on claims that Phreesia violated the Securities Exchange Act of 1934 by issuing materially false statements to the market. According to the complaint, the company touted its pharmaceutical marketing commitments as a primary driver for the Network Solutions segment, despite internal uncertainties that threatened to undermine its revenue targets. Investors who suffered financial losses due to these allegedly misleading disclosures are encouraged to contact the Schall Law Firm before the July 13, 2026, deadline.

Brian Schall of the Los Angeles-based firm is handling inquiries from shareholders wishing to discuss their legal rights. While the class has not yet been formally certified, those who purchased securities during the specified period remain absent class members unless they take action. The firm, which specializes in shareholder rights litigation, offers consultations to potential plaintiffs to evaluate their standing in the case.